PLASTICELL

History

Year	Detail
2002	Plasticell, a U.K.-based start-up biotechnology company, was founded by scientist and entrepreneur Dr. Yen Choo to commercialize an innovative high-throughput technology for cell biology.
2008	The company acquired the rights to six human embryonic stem cell lines from Axordia Ltd (Sheffield, UK). These lines are specialized cells capable of forming all body tissues and are a source of human cells for research and transplantation therapy.
2010	The company signed a screening collaboration with UCB, a biopharmaceutical company, to supply Plasticell with drug compound libraries with known biological targets.
2010	The company collaborated with Sigma-Aldrich, a provider of technologies and reagents to the life science research market, to produce novel turnkey solutions for stem cell research.
2016	Plasticell collaborated with Sphere Fluidics to develop gene transduction technology that leads to safer and more efficient gene therapies.
2016	Plasticell and CellSpring collaborated to validate osteogenic cell therapy and 3D cell culture models for high-performance drug screening.
2017	The company signed a stem cell research collaboration with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
2017	The company collaborated with GSK to use its combinatorial stem cell screening technology, CombiCult, to optimize the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for GSK's therapeutic research.